GlaxoSmithKline Pakistan Limited
Pharmaceutical company · 185 brands · 209 molecules
Ranked #17 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems
Company overview
GlaxoSmithKline Pakistan Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 185 product registrations across 209 distinct molecules. It is the 85th largest registrant in Pakistan by product count, and ranks 17th of 213 in Other Beta-Lactam, Cephalosporins & Penems. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Anti-Infectives. DRAP has issued 1 alert involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Reported financials
PSX-listed · fiscal year 2024 (Dec 31, 2024)
23% YoY revenue growth, double-digit growth across key brands. Gross margin improved to 25.2% from 2.5% (deregulation enabled price increases)
Source: company filing
Products by GlaxoSmithKline
232 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
1 alert in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for GlaxoSmithKline
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included